What it's for (Indications)
- Alendronate sodium with cholecalciferol is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
- It is also approved for increasing bone mass in men with osteoporosis and for the treatment of osteoporosis in men and women receiving glucocorticoid therapy.
- The cholecalciferol component (Vitamin D3) addresses vitamin D insufficiency, which is highly prevalent in osteoporotic patients and crucial for optimal calcium absorption and bone mineralization.
- This combination therapy aims to reduce the risk of vertebral and hip fractures by improving bone mineral density and supporting overall bone health, enhancing the therapeutic efficacy of alendronate and contributing to bone mineralization and calcium homeostasis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical dosage for alendronate sodium with cholecalciferol for the treatment and prevention of osteoporosis is one tablet (containing 70 mg alendronate and either 2800 IU or 5600 IU cholecalciferol) taken orally once weekly. It is imperative that the tablet be taken with a full glass of plain water (at least 6-8 fluid ounces) first thing in the morning upon arising, at least 30 minutes before the first food, beverage, or medication of the day. Patients must remain upright (sitting or standing) for at least 30 minutes after taking the dose and until after their first food of the day to minimize the risk of esophageal irritation and adverse events. Chewing, sucking, or crushing the tablet should be avoided. Supplemental calcium and vitamin D should be considered if dietary intake is inadequate, but not taken simultaneously with the alendronate/cholecalciferol dose. |
Safety & Warnings
Common Side Effects
- Common side effects associated with alendronate include gastrointestinal disturbances such as abdominal pain, dyspepsia, nausea, constipation, diarrhea, and esophageal irritation (e.
- g.
- , esophagitis, esophageal ulcers, erosions).
- Less common but serious adverse effects include osteonecrosis of the jaw (ONJ), particularly in patients with cancer, those undergoing dental procedures, or those on corticosteroids.
- Atypical femoral fractures (AFFs) can occur with minimal or no trauma, typically in the subtrochanteric and diaphyseal regions of the femur, often after prolonged use.
- Other potential side effects include severe musculoskeletal pain, headache, dizziness, rash, and rarely, severe allergic reactions including angioedema and Stevens-Johnson syndrome.
- Symptoms of hypercalcemia or hypervitaminosis D are rare at therapeutic doses of cholecalciferol but can occur with excessive intake, manifesting as nausea, vomiting, polyuria, weakness, and elevated serum calcium levels, necessitating careful monitoring.
Serious Warnings
- Black Box Warning: Serious Warnings: While alendronate sodium with cholecalciferol does not carry an official FDA boxed warning, several serious and potentially debilitating adverse events warrant explicit caution. Healthcare professionals and patients must be aware of the risk of osteonecrosis of the jaw (ONJ), particularly in individuals with pre-existing dental disease, invasive dental procedures, cancer, or those receiving chemotherapy or corticosteroids. Prior to initiating therapy, a comprehensive dental examination with appropriate preventive dentistry should be considered, especially for patients with identified risk factors. Atypical femoral fractures (AFFs), characterized by new or unusual pain in the thigh, hip, or groin, have been reported in patients on bisphosphonate therapy, with prolonged use potentially increasing risk. Patients should report any such pain immediately for evaluation. Severe and occasionally incapacitating bone, joint, and/or muscle pain has also been reported; consider discontinuing the drug if symptoms are severe and persistent. Additionally, serious esophageal adverse events, including esophagitis, ulcers, and erosions, sometimes leading to hemorrhage, stricture, or perforation, can occur if dosing instructions are not followed precisely. Strict adherence to administration guidelines is crucial to mitigate these significant risks and ensure patient safety.
- Patients should be advised of the potential for serious esophageal adverse reactions, including esophagitis, esophageal ulcers, and erosions, which can rarely lead to stricture or perforation.
- These risks are significantly minimized by adhering strictly to the dosing instructions, including taking the medication with sufficient water and remaining upright for at least 30 minutes.
- Pre-existing hypocalcemia must be corrected before initiating therapy due to alendronate's potential to decrease serum calcium.
- There is a risk of osteonecrosis of the jaw (ONJ), especially after tooth extraction or other dental procedures, particularly in patients with cancer, receiving chemotherapy, corticosteroids, or with poor oral hygiene.
- Atypical femoral fractures (AFFs) have been reported; patients presenting with new or worsening thigh, hip, or groin pain should be evaluated for a potential fracture.
- Severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported; consider discontinuing the drug if symptoms are severe and persistent.
- Renal impairment necessitates dose adjustment or contraindication.
How it Works (Mechanism of Action)
Alendronate is a potent, nitrogen-containing bisphosphonate that primarily acts as a specific inhibitor of osteoclast-mediated bone resorption. It preferentially localizes to sites of active bone remodeling, especially under osteoclasts, and incorporates into the bone matrix. When osteoclasts attempt to resorb alendronate-containing bone, the drug is released and internalized by the osteoclasts, disrupting their mevalonate pathway. This inhibition leads to a reduction in osteoclast activity, apoptosis of osteoclasts, and consequently, a decrease in bone turnover and bone loss, allowing bone formation to catch up. Cholecalciferol (Vitamin D3) is a precursor to calcitriol, the active form of vitamin D. Calcitriol plays a critical role in maintaining calcium and phosphate homeostasis by promoting their absorption from the gastrointestinal tract, stimulating bone mineralization, and influencing parathyroid hormone secretion. This combined action ensures adequate mineral availability for bone health while directly inhibiting bone breakdown, thereby increasing bone mineral density and reducing fracture risk.